[EN] SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS [FR] DÉRIVÉS BICYCLIQUES SUBSTITUÉS D'IMIDAZOLE COMME MODULATEURS DE LA GAMMA-SÉCRÉTASE
[EN] SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS [FR] DÉRIVÉS BICYCLIQUES SUBSTITUÉS D'IMIDAZOLE COMME MODULATEURS DE LA GAMMA-SÉCRÉTASE
[EN] NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES SUBSTITUÉS EN TANT QUE MODULATEURS DE LA GAMMA-SÉCRÉTASE
申请人:ORTHO MCNEIL JANSSEN PHARM
公开号:WO2010089292A1
公开(公告)日:2010-08-12
The present invention is concerned with substituted bicyclic heterocyclic compounds of Formula (I) wherein Het1, Het2, A1, A2, A3 and A4 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS
申请人:Janssen Pharmaceuticals, Inc.
公开号:EP2393804B1
公开(公告)日:2014-04-16
SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS
申请人:Gijsen Henricus Jacobus Maria
公开号:US20110237580A1
公开(公告)日:2011-09-29
The present invention is concerned with novel substituted bicyclic imidazole derivatives of Formula (I)
wherein R
0
, R
1
, R
3
, R
4
, X, A
1
, A
2
, A
3
, A
4
, Y
1
, Y
2
and Y
3
have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said novel compound as an active ingredient as well as the use of said compounds as a medicament.
BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
申请人:ARRAY BIOPHARMA INC.
公开号:US20160355517A1
公开(公告)日:2016-12-08
Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.